A pioneering medical trial has found that delivering regenerative cells to fetuses suffering from spina bifida as part of a surgical repair may represent a "important advancement" in managing prenatal disorders.
Study Parameters and Security
The US-based trial examined six unborn babies with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord while the defect was being closed.
Importantly, the regenerative treatment proved to be secure. The study team reported that the treatment did not lead to tumors, disrupt the healing process, or block the correction of associated brain abnormalities.
Positive Developments
Post-birth MRI scans indicated a complete reversal of Chiari malformation in each of the babies. This neurological improvement is strongly associated with improved motor skills and quality of life.
"Should it enable a greater number of infants capable of walking who previously could not, it could establish itself as the new treatment paradigm," noted the study director. "The results are profoundly encouraging and pave the way for numerous possible novel therapies."
Long-Term Prospects and Optimism
Independent medical specialists have suggested that additional validation of these apparent benefits could announce a "new era" in fetal surgery. The potential to improve nerve function impairment occurring during fetal development is viewed as a transformative goal.
Particularly welcome would be better management of continence and digestive health, which are typical difficulties for those diagnosed with this condition.
Looking Ahead
Although this preliminary study was small in scale, its confirmed tolerability and hopeful trends provide a strong foundation for expanded clinical research. The combination of regenerative medicine with proven prenatal surgical methods presents significant potential for improving the prognosis for future generations with myelomeningocele.